I thank Ragozzino et al. (1) for their thoughtful comment in this issue of Diabetes on my recent article (2) and am pleased to hear that they consider my article a timely synthesis of emerging evidence on the relationship between type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD). I fully agree with Ragozzino et al. that there is a bidirectional relationship between type 2 diabetes and MASLD and that MASLD contributes to the pathogenesis of type 2 diabetes. In fact, my colleagues and I were the first to coin the term hepatokines in 2008 (3), describing the role of proteins that are dysregulated in MASLD and that impact other organs and tissues. Since then, my colleagues and I have carefully investigated several hepatokines for their role in the pathogenesis of type 2 diabetes and cardiovascular disease (4). Nevertheless, based on the emerging clinical burden of MASLD and the fact that people with type 2 diabetes and MASLD have a substantially higher risk of developing hepatic decompensation and hepatocellular carcinoma, compared with people with MASLD but without type 2 diabetes (2), it is justified that MASLD be described as a complication of diabetes. Indeed, the “complication” terminology has not yet been addressed in the MASLD guidelines, but this will soon change as more data emerge in this field of research.
Source link

Leave a Reply